Survey: Limited Access to Medical Marijuana Laws

Description: 

Eighteen states have adopted Limited Access Marijuana Product Laws permitting only low (or zero) Tetrahydrocannabinol (THC) and high Cannabidiol (CBD) products to treat several, often specified conditions, usually uncontrolled epilepsy disorders. THC is the psychoactive substance in marijuana that alters users’ senses and cause mood changes, and can lead to changes in behavior. Cannabidiol, however, has mild psychoactive effects. This resource, developed by the Network for Public Health Law and released on July 19, 2017, provides a brief overview of jurisdictions with statutory and regulatory provisions legalizing limited access medical marijuana programs. The survey complements the network's other survey results on Medical Marijuana Programs.

For more information about the document, go to https://www.networkforphl.org/resources_collection/2017/07/19/911/survey_limited_access_to_medical_marijuana_laws/?utm_source=Network+Report+7-20-17&utm_campaign=Network+Report+7-20-17&utm_medium=email&utm_content=312.

 

Primary Topic Areas: 
Tags: 
Original Publication Year: 
2017
Event/Publication Date: 
July, 2017

Contact Us

INTERNATIONAL SOCIETY FOR
DISEASE SURVEILLANCE

288 Grove Street, Box 203
Braintree, MA 02184
(617) 779 0880
Email:syndromic@syndromic.org

This Knowledge Repository is made possible through the activities of the Centers for Disease Control and Prevention Cooperative Agreement/Grant #1 NU500E000098-01, National Surveillance Program Community of Practice (NSSP-CoP): Strengthening Health Surveillance Capabilities Nationwide, which is in the interest of public health.